OCT provides prognostic data in patients with CRVO

Optical coherence tomography may provide predictive information after 3 months of treatment with ranibizumab in patients with central retinal vein occlusion, according to a study.Investigators evaluated time-domain OCT findings for 397 branch retinal vein occlusion patients from the BRAVO study and 392 central retinal vein occlusion patients from the CRUISE study. Patients received 0.3-mg or 0.5-mg injections of Lucentis (ranibizumab, Genentech) or placebo.

Full Story →